ABBVIE

REGENXBIO's ABBV-RGX-314 gene therapy for wet AMD reduced antiVEGF injections by 97% in 9 patients with bilateral disease, with 78% injection-free post-treatment. Safety was well-tolerated, with no serious adverse events. This marks the first bilateral treatment for wet AMD, potentially offering a one-time effective treatment.

Clinical trial dropout rates are high, often due to burdensome participation. The pandemic accelerated patient-centric technologies but created data silos. Decentralized clinical trials (DCTs) emerged, though most patients prefer hybrid models. Early DCT tech was flawed, leading to hybrid solutions. Increasing trial diversity is hindered by lack of robust data. Future success hinges on integrating data, easy patient access, validated sensor data, and adhering to FDA guidelines on DCTs and diversity.

FDA approves Allergan Aesthetics' Botox Cosmetic for treating moderate to severe vertical platysma bands, offering a nonsurgical option for neck band improvement. Phase III studies showed significant improvement and patient satisfaction. Potential adverse effects include excessive weakness and dysphagia.

The ADC market, driven by technological advancements and personalized medicine, is expected to reach ~USD 26 billion by 2030 with a CAGR of ~14%. North America leads due to high cancer incidence and strong biopharmaceutical sector. Key players include F. Hoffmann-La Roche Ltd, DAIICHI SANKYO COMPANY, LIMITED, and Pfizer Inc. The market is dynamic, influenced by regulatory frameworks and innovation in linker technologies and payloads.

Asthma drug market focuses on quick-relief and long-term control meds; market driven by asthma prevalence, research advancements, and improved diagnostics; projected to reach $64.6 billion by 2033; major companies include Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sanofi, Pfizer, Teva, and AbbVie.

AbbVie announced that nine provinces have accelerated public coverage of EPKINLY™, a treatment for adult patients with Relapsed or Refractory diffuse large B-cell lymphoma (R/R DLBCL). EPKINLY is indicated after two or more lines of systemic therapy in patients who have previously received or are unable to receive CAR-T cell therapy. The treatment is now publicly funded in almost all remaining provinces, including Nova Scotia, British Columbia, Saskatchewan, Manitoba, and Newfoundland & Labrador.

ABBV-RGX-314 shows 97% reduction in treatment burden at nine months, with zero cases of intraocular inflammation and potential for bilateral wet AMD treatment.

BOTOX® Cosmetic receives FDA approval for temporary improvement in appearance of moderate to severe vertical bands connecting jaw and neck (platysma bands) in adults, expanding its aesthetic indications to include forehead lines, frown lines, crow’s feet lines, and now platysma bands.

Allergan Aesthetics, an AbbVie company, announced US FDA approval of Botox Cosmetic for temporary improvement in moderate to severe vertical bands connecting the jaw and neck. This marks the fourth aesthetic indication for Botox Cosmetic, expanding its use beyond facial lines. Clinical studies showed significant improvement in platysma band appearance, with 65% and 62% of patients reporting satisfaction 14 days post-treatment.